Hormone-sensitive Prostate Cancer
📧 Sign up to get email alerts when something new happens for Hormone-sensitive Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer [Phase 3]
A Phase III clinical trial evaluating rezvilutamide for metastatic hormone-sensitive prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
This clinical trial assesses whether minimal residual disease can predict therapeutic efficacy in metastatic hormone-sensitive prostate canc…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. [Phase 3]
This clinical trial update outlines the Phase III REINFORCE trial evaluating intensification with docetaxel plus apalutamide in metastatic h…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer [Phase 2]
A Phase 2 clinical trial (CONVERT-HB1) evaluating radical prostatectomy after systemic therapy for patients with high-volume metastatic horm…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
This clinical trial update describes a study investigating quality of life, functional, and cognitive outcomes in patients with metastatic h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer [Phase 4]
Clinical trial update for a Phase 4 study (PSMAtrack) assessing PSMA-PET imaging changes during initial therapy for metastatic hormone-sensi…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide [Phase 2]
Phase 2 clinical trial evaluating the effect of androgen receptor–directed therapies (darolutamide or enzalutamide) on cognitive function in…
-
CLINICAL_TRIALS research · 2025-10-29Clinical Trial Update: Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer [Phase 2]
A Phase II clinical trial evaluating PSA-triggered, individualized management for metastatic hormone-sensitive prostate cancer, currently re…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer [Phase 3]
Phase 3 randomized platform trial investigating treatments for metastatic hormone-sensitive prostate cancer; the study is currently recruiti…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients
This clinical trial update covers apalutamide in metastatic hormone-sensitive prostate cancer. The trial is currently active but not recruit…
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics
A clinical trial from Anhui Medical University aims to study castration-resistant prostate cancer progression and immune interactions in met…
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment [NA]
A randomized trial compares abiraterone acetate plus androgen deprivation therapy (APA+ADT) versus APA+ADT with local treatment in metastati…
-
CLINICAL_TRIALS research · 2025-06-22Clinical Trial Update: Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
This clinical trial update describes a planned evaluation of triplet therapy with darolutamide plus androgen-deprivation therapy and docetax…
-
CLINICAL_TRIALS trial_result · 2025-05-29Clinical Trial Update: Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer [Phase 2]
A Phase 2 trial update reports completing the study investigating combining EPI-7386 with enzalutamide and androgen deprivation therapy in m…
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer [Phase 3]
Phase 3 biomarker-driven trial (ProBio) in metastatic prostate cancer is currently recruiting, enrolling patients with metastatic castration…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients [Phase 3]
Phase 3 trial comparing Docetaxel 75 mg/m2 every 3 weeks versus 50 mg/m2 every 2 weeks, in combination with darolutamide and androgen depriv…
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) [Phase 3]
Phase 3 trial update evaluating standard of care with or without lutetium-177 Lu-PSMA-617 in newly diagnosed metastatic hormone-sensitive pr…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
This completed DECIDER trial evaluated patient preferences for prostate cancer treatment attributes using a survey-based discrete choice exp…
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care
An observational study conducted in Belgium assessing the use of darolutamide as part of combination therapy for metastatic hormone-sensitiv…
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC [Phase 2]
Phase 2 clinical trial update reporting on the safety and tolerability of GT0918 in patients with metastatic hormone-sensitive and castratio…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) [Phase 3]
Phase 3 trial evaluating pembrolizumab plus enzalutamide and ADT versus placebo plus enzalutamide and ADT in metastatic hormone-sensitive pr…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) [Phase 3]
This Phase 3 trial assesses pembrolizumab added to enzalutamide plus androgen deprivation therapy versus placebo added to enzalutamide plus …
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [Phase 3]
Phase 3 trial evaluating enzalutamide plus androgen deprivation therapy versus placebo plus ADT in Chinese men with metastatic hormone-sensi…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension [Phase 3]
Phase 3 China extension of KEYNOTE-991 assessed pembrolizumab plus enzalutamide plus androgen deprivation therapy vs placebo plus enzalutami…
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC [Phase 3]
A Phase 3 clinical trial comparing a 6-month versus long-term course of Rezvilutamide with ADT and chemotherapy in metastatic hormone-sensit…